BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7812359)

  • 1. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma.
    Springer GF; Desai PR; Tegtmeyer H; Carlstedt SC; Scanlon EF
    Cancer Biother; 1994; 9(1):7-15. PubMed ID: 7812359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma.
    Springer GF; Desai PR; Spencer BD; Tegtmeyer H; Carlstedt SC; Scanlon EF
    Cancer Detect Prev; 1995; 19(4):374-80. PubMed ID: 7553680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T and Tn pancarcinoma markers: autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast carcinoma immunotherapy.
    Springer GF
    Crit Rev Oncog; 1995; 6(1):57-85. PubMed ID: 8573608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy.
    Springer GF
    J Mol Med (Berl); 1997 Aug; 75(8):594-602. PubMed ID: 9297627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
    Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
    J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
    J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with Theratope (STn-KLH) as treatment for breast cancer.
    Holmberg LA; Sandmaier BM
    Expert Rev Vaccines; 2004 Dec; 3(6):655-63. PubMed ID: 15606349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.
    Morse MA; Hobeika A; Osada T; Niedzwiecki D; Marcom PK; Blackwell KL; Anders C; Devi GR; Lyerly HK; Clay TM
    J Transl Med; 2007 Sep; 5():42. PubMed ID: 17822557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer.
    Tiriveedhi V; Tucker N; Herndon J; Li L; Sturmoski M; Ellis M; Ma C; Naughton M; Lockhart AC; Gao F; Fleming T; Goedegebuure P; Mohanakumar T; Gillanders WE
    Clin Cancer Res; 2014 Dec; 20(23):5964-75. PubMed ID: 25451106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival.
    Kurtenkov O; Klaamas K; Rittenhouse-Olson K; Vahter L; Sergejev B; Miljukhina L; Shljapnikova L
    Exp Oncol; 2005 Jun; 27(2):136-40. PubMed ID: 15995632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local therapy and survival in breast cancer.
    Punglia RS; Morrow M; Winer EP; Harris JR
    N Engl J Med; 2007 Jun; 356(23):2399-405. PubMed ID: 17554121
    [No Abstract]   [Full Text] [Related]  

  • 12. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.
    Touboul E; Buffat L; Belkacémi Y; Lefranc JP; Uzan S; Lhuillier P; Faivre C; Huart J; Lotz JP; Antoine M; Pène F; Blondon J; Izrael V; Laugier A; Schlienger M; Housset M
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):25-38. PubMed ID: 9989511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer.
    Touboul E; Buffat L; Lefranc JP; Blondon J; Deniaud E; Mammar H; Laugier A; Schlienger M
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1019-28. PubMed ID: 8600084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.
    Ravindranathan S; Nguyen KG; Kurtz SL; Frazier HN; Smith SG; Koppolu BP; Rajaram N; Zaharoff DA
    Breast Cancer Res; 2018 Oct; 20(1):126. PubMed ID: 30348199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma.
    Peng B; Liang L; Chen Z; He Q; Kuang M; Zhou F; Lu M; Huang J
    Hepatogastroenterology; 2006; 53(69):409-14. PubMed ID: 16795983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
    Holmberg LA; Oparin DV; Gooley T; Lilleby K; Bensinger W; Reddish MA; MacLean GD; Longenecker BM; Sandmaier BM
    Bone Marrow Transplant; 2000 Jun; 25(12):1233-41. PubMed ID: 10871727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
    Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
    J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of conservative treatment of stage I-II carcinoma of the breast. Analysis of 311 patients].
    Antonello M; Polico R; Busetto M; Pizzi G
    Radiol Med; 1992 Oct; 84(4):440-3. PubMed ID: 1455028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.